Recent Warnings about Antihypertensive Drugs and Cancer Risk: Where Do They Come From?
The recent decrease in mortality related to cardiovascular diseases has largely been due to the more effective treatment of cardiovascular risk factors and secondary prevention therapies. More people than ever are now on long-term medications. Hypertension, which is one of the most common cardiovasc...
Guardado en:
Autores principales: | Allegra Battistoni, Massimo Volpe |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/84f34272bea54693a13e804da2d6d9d3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?
por: Gianluigi Savarese
Publicado: (2019) -
Sleep Apnoea and AF: Where Do We Stand? Practical Advice for Clinicians
por: Suneet Mittal, et al.
Publicado: (2021) -
Personalised Approaches to Improving the Effect of Anti-platelet Agents: Where Do We Stand?
por: Lucas C Godoy, et al.
Publicado: (2019) -
Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart
por: Emilia D’Elia, et al.
Publicado: (2020) -
Electrophysiology’s Identity Crisis: What our Clinical Trials Do and Do Not Say About Us
por: David J Callans, et al.
Publicado: (2020)